Changzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Department of Endocrinology and Metabolism, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
J Bone Miner Metab. 2021 Jul;39(4):631-638. doi: 10.1007/s00774-020-01200-3. Epub 2021 Feb 10.
Periostin, as an emerging biomarker, is involved in multiple steps in bone metabolism. This study aimed to investigate the correlation between periostin levels and bone mineral density as well as bone turnover markers in postmenopausal women with type 2 diabetes (T2DM).
This study was a cross-sectional study that included 164 postmenopausal women with T2DM as study subjects and 32 age-matched nondiabetic postmenopausal women with normal bone mineral density (BMD) as healthy control subjects. A total of 164 subjects with T2DM were then divided into three groups according to BMD: the normal BMD group (n = 29), the osteopenia group (n = 70), and the osteoporosis group (n = 65). The clinical data of all subjects along with the relevant biochemical parameter data were collected. Plasma periostin was detected using an enzyme-linked immunosorbent assay (ELISA).
Plasma periostin levels were significantly increased in T2DM patients with normal BMD compared with healthy controls (p < 0.05). In the diabetic group, plasma periostin levels were significantly elevated with decreased BMD, were positively correlated with osteocalcin levels (r = 0.162, p = 0.039) and were inversely associated with femoral neck BMD (r = - 0.308, p < 0.001) and total femur BMD (r = - 0.295, p < 0.001). In the case of chronic complications, periostin levels were slightly increased in individuals with complications of diabetic retinopathy, diabetic nephropathy and fracture (p > 0.05).
The current study demonstrated that plasma periostin levels were significantly associated with BMD in patients with T2DM, and periostin might act as a novel biochemical marker of osteoporosis in postmenopausal women with type 2 diabetes.
作为一种新兴的生物标志物，骨纤连蛋白（periostin）参与了骨代谢的多个步骤。本研究旨在探讨绝经后 2 型糖尿病（T2DM）患者中骨纤连蛋白水平与骨密度（BMD）和骨转换标志物之间的相关性。
本研究为横断面研究，纳入 164 例绝经后 T2DM 患者作为研究对象，32 例年龄匹配且 BMD 正常的绝经后非糖尿病女性作为健康对照组。根据 BMD 将 164 例 T2DM 患者分为三组：正常 BMD 组（n=29）、骨量减少组（n=70）和骨质疏松组（n=65）。收集所有受试者的临床资料和相关生化参数。采用酶联免疫吸附试验（ELISA）检测血浆骨纤连蛋白水平。
与健康对照组相比，正常 BMD 的 T2DM 患者的血浆骨纤连蛋白水平显著升高（p<0.05）。在糖尿病组中，随着 BMD 的降低，血浆骨纤连蛋白水平显著升高，与骨钙素水平呈正相关（r=0.162，p=0.039），与股骨颈 BMD（r=-0.308，p<0.001）和全股骨 BMD（r=-0.295，p<0.001）呈负相关。在慢性并发症方面，合并糖尿病视网膜病变、糖尿病肾病和骨折的患者骨纤连蛋白水平略有升高（p>0.05）。
本研究表明，T2DM 患者的血浆骨纤连蛋白水平与 BMD 显著相关，骨纤连蛋白可能是绝经后 2 型糖尿病女性骨质疏松的一种新型生化标志物。
